TAS-103 dihydrochloride is a dual inhibitor of DNA topoisomerase I/II , used for cancer research. In Vitro TAS-103 is a dual inhibitor of DNA topoisomerase I/II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC 50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103. TAS-103 inhibits the viability of HeLa cells, with an IC 50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo TAS-103 (30 mg/kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal administration Lewislung carcinoma (LLC) cells are diluted with DMEM to obtain 5×10 6 cells/mL suspension, and 0.2 mL of the suspension is carefully injected subcutaneously into five-week-old C57BL/6 male mice . Liposomal TAS-103 (0.2 mL/mouse, 30 mg/kg as TAS-103 ), free TAS-103 or PBS is injected intravenously into a tail vein of the tumor-bearing mice on days 4, 8, and 12 after tumor implantation. Tumor volume of each mouse and the body weight change as an indicator of side effect are monitored daily thereafter. Tumor volume is calculated . aladdin has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Topoisomerase I Topoisomerase II